Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Jan
14
Today In Oncology
Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Multiple Myeloma Sex Differences in Etiology and Clinical Presentation
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive mCRPC
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo